



6940 Columbia Gateway Drive | Suite 110 | Columbia, MD 21046
 410-884-2900
 www.biosafetycorp.com | clientservices@biosafetycorp.com

SUBMISSION FORM IBC B: PROTOCOL REVIEW

Date:
Protocol ID:
Project Title:

I. PROTOCOL

		Yes	No
1a.	Has the protocol been granted a vaccine exemption under Appendix M-VI-A? <i>* If yes, please attach copy of the vaccine exemption correspondence received from NIH OBA.</i>	<input type="checkbox"/>	<input type="checkbox"/>
1b.	Has this protocol ever been reviewed by another IBC on behalf of this institution? <i>*If yes, please explain:</i>	<input type="checkbox"/>	<input type="checkbox"/>
1c.	Date the IND application for this protocol went into effect: <input type="checkbox"/> Pending <i>Please ask your sponsor, this related to compliance with annual NIH reporting requirements</i>		
1d.	Do you have a specific calendar requirement for opening enrollment? <i>*If yes, date:</i> <i>Explanation:</i>	<input type="checkbox"/>	<input type="checkbox"/>

II. PRINCIPAL INVESTIGATOR INFORMATION

2a.	Name:	Degree(s):	Specialty:
2b.	Address:		
2c.	Phone:	Email:	
2d.	Has the PI delegated reporting responsibilities (per NIH guidelines Appendix M-1-C) to another party, such as a corporate sponsor? <i>*If yes, forward a copy of the delegation letter submitted to NIH OBA. Be aware delegation itself does not fulfill the NIH reporting requirement. If the sponsor does not report, the PI must.</i>		Yes <input type="checkbox"/> No <input type="checkbox"/>
2e.	Has the PI ever been debarred or disqualified from participating in clinical research by any regulatory authority? <i>*If yes, please attach a description of the circumstances and current status</i>		<input type="checkbox"/> <input type="checkbox"/>
2f.	Are staff who prepare and administer the investigational agent qualified to do so under local and state laws? <i>*If no, please explain:</i>		<input type="checkbox"/> <input type="checkbox"/>

III. PI REPRESENTATIVE INFORMATION

The PI representative is the person designated as the primary contact for IBC review.

3a.	PI Representative Name:
3b.	Title:
3c.	Address:
3d.	Phone: Email:

IV. RESEARCH LOCATION

List all facilities where study agent will be present and where subjects received required post-dosing care.

4a.	Main Site, Name:
4b.	Address:
4c.	Phone: Email:
4d.	Type of facility: <input type="checkbox"/> Outpatient medical office <input type="checkbox"/> Hospital <input type="checkbox"/> Other (specify):

4e. What study activities will be done at this site?
 Agent receiving or shipping Agent Storing Agent Preparation Dosing
 Specimen collection Other subject medical care or follow-up Other (specify):

4f. Additional Site Name:
 4g. Address:
 4h. Phone: Email:
 4i. Type of facility: Outpatient medical office Hospital Other (specify):
 4j. What study activities will be done at this site?
 Agent receiving or shipping Agent Storing Agent Preparation Dosing
 Specimen collection Other subject medical care or follow-up Other (specify):
To list more sites, please attach additional sheets

V. ADDITIONAL CONTACT INFORMATION

5a. Sponsor Name:
 5b. Address:
 5c. Contact Name:
 5d. Phone: Email:
 6a. Medical Monitor Name:
 6b. Phone: Email:
 7a. CRO Name:
 7b. Address:
 7c. Phone: Email:
 8a. SMO Name:
 8b. Address:
 8c. Phone: Email:
 9a. IRB Name:
 9b. Address:
 9c. Phone: Email:

VI. BILLING INFORMATION

10a. Party to be billed:
 10b. Address:
 10c. Phone: Email:
 10d. Special instructions:

VII. PERSON COMPLETING THIS FORM

11a. Name and Title:
 11b. Phone: